Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kurtis Opp

Physician Assistant, Medical San Francisco, CA Physician Assistant

NPI 1275627796 CMS profile 10942135

45 Castro St, Suite 332, San Francisco, CA 94114

Open in the dashboard

General payments

$19,113

727 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kurtis Opp of San Francisco, CA is reported in the CMS Open Payments database as having received $19,113 across 727 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,906 179
2024 General $5,088 164
2023 General $3,900 151
2022 General $2,724 119
2021 General $2,494 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kurtis Opp
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kurtis Opp were reported at $4,906. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kurtis Opp Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,494 $156 $41–$563 $132
2022 $2,724 $185 $55–$649 $149
2023 $3,900 $199 $58–$717 $160
2024 $5,088 $206 $62–$740 $164
2025 $4,906 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,995 135 payments
  2. Genzyme Corporation $2,501 47 payments
  3. LEO Pharma Inc. $1,746 118 payments
  4. Lilly USA, LLC $1,495 44 payments
  5. Pfizer Inc. $989 43 payments
  6. Incyte Corporation $984 41 payments
  7. Regeneron Healthcare Solutions, Inc. $917 37 payments
  8. Arcutis Biotherapeutics, Inc. $788 21 payments
  9. Galderma Laboratories, L.P. $758 28 payments
  10. Sun Pharmaceutical Industries Inc. $720 27 payments
  11. Other $5,220 186 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,819 723 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,064 1 payment
  3. Education $230 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $2,521 53 payments
  2. SKYRIZI $1,488 62 payments
  3. ADBRY $1,431 93 payments
  4. TALTZ $1,140 41 payments
  5. OPZELURA $984 41 payments
  6. VTAMA $870 25 payments
  7. RINVOQ $817 50 payments
  8. DUPIXENT Inflammation And Immunology $693 27 payments
  9. Zoryve $555 16 payments
  10. NEMLUVIO $538 17 payments
  11. Other $8,585 368 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

257

Median for Physician Assistant: 241

Drug cost

$72,660

Median for Physician Assistant: $4,110

Branded share of claims

4.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 11 $60,770
Metronidazole Generic 23 $3,433
Tacrolimus Generic 15 $2,359
Ketoconazole Generic 48 $1,351
Clobetasol Propionate Generic 13 $1,208
Doxycycline Hyclate Generic 33 $1,184
Tretinoin Generic 11 $995
Betamethasone Dipropionate Generic 18 $618
Mupirocin Generic 48 $376
Triamcinolone Acetonide Generic 37 $368

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $1,535
  • Regeneron Healthcare Solutions, Inc. $155
$1,690 — —
SKYRIZI
  • AbbVie, Inc. $553
$553 — —
RINVOQ
  • AbbVie, Inc. $323
$323 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $283
$283 — —
VTAMA
  • Dermavant Sciences, Inc. $280
$280 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

727 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record